Bristol Myers Squibb (BMY) Return on Capital Employed (2009 - 2026)
Bristol Myers Squibb (BMY) reported Return on Capital Employed of 6.84% for Q1 2026, up 479.0% year-over-year from 1.18% in Q1 2025, and down 4.01% on a QoQ basis from 6.58% in Q4 2025.
Bristol Myers Squibb (BMY) has 17 years of Return on Capital Employed data on file, last reported at 6.84% in Q1 2026.
- Quarterly Return on Capital Employed rose 479.0% year-over-year to 6.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.84% (up 479.0% YoY) and the FY2025 annual result came in at 6.79%, up 2509.0% from the prior year.
- Return on Capital Employed slipped to 6.84% in Q1 2026 per BMY's latest filing, from 6.58% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1.88% in Q1 2023 and bottomed at 32.22% in Q4 2024.
- The 5-year median for Return on Capital Employed is 6.58% (2025), against an average of 10.25%.
- The widest annual swing landed in 2024, when Return on Capital Employed sank 2904 bps; it then soared 2564 bps in 2025.
- Tracing BMY's Return on Capital Employed over 5 years: stood at 3.21% in 2022, then advanced by 1 bps to 3.18% in 2023, then tumbled by 915 bps to 32.22% in 2024, then jumped by 80 bps to 6.58% in 2025, then declined by 4 bps to 6.84% in 2026.
- Per Business Quant, the three latest BMY Return on Capital Employed figures stand at 6.84% (Q1 2026), 6.58% (Q4 2025), and 9.78% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -6.84% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.84% |
| Dec 31, 2025 | -6.58% |
| Sep 30, 2025 | -9.78% |
| Jun 30, 2025 | -11.48% |
| Mar 31, 2025 | -11.63% |
| Dec 31, 2024 | -32.22% |
| Sep 30, 2024 | -26.26% |
| Jun 30, 2024 | -24.29% |
| Mar 31, 2024 | -23.72% |
| Dec 31, 2023 | -3.18% |
| Sep 30, 2023 | -2.78% |
| Jun 30, 2023 | -2.29% |
| Mar 31, 2023 | -1.88% |
| Dec 31, 2022 | -3.21% |
| Sep 30, 2022 | -2.72% |
| Jun 30, 2022 | -2.70% |
| Mar 31, 2022 | -2.78% |
| Dec 31, 2021 | -2.09% |
| Sep 30, 2021 | -16.45% |
| Jun 30, 2021 | -16.00% |
| Mar 31, 2021 | -15.27% |
| Dec 31, 2020 | -18.11% |
| Sep 30, 2020 | -7.43% |
| Jun 30, 2020 | -7.70% |
| Mar 31, 2020 | -6.54% |
| Dec 31, 2019 | -4.12% |
| Sep 30, 2019 | -1.28% |
| Jun 30, 2019 | 1.06% |
| Mar 31, 2019 | -2.07% |
| Dec 31, 2018 | -2.10% |
| Sep 30, 2018 | -5.52% |
| Jun 30, 2018 | -9.62% |
| Mar 31, 2018 | -5.82% |
| Dec 31, 2017 | -3.65% |
| Sep 30, 2017 | -1.24% |
| Jun 30, 2017 | 1.45% |
| Mar 31, 2017 | 4.16% |
| Dec 31, 2016 | 3.80% |
| Sep 30, 2016 | -0.40% |
| Jun 30, 2016 | -1.88% |
| Mar 31, 2016 | -7.55% |
| Dec 31, 2015 | -7.71% |
| Sep 30, 2015 | -6.05% |
| Jun 30, 2015 | -5.47% |
| Mar 31, 2015 | -3.72% |
| Dec 31, 2014 | -6.17% |
| Sep 30, 2014 | -3.66% |
| Jun 30, 2014 | -5.01% |
| Mar 31, 2014 | -4.64% |
| Dec 31, 2013 | -6.84% |
| Sep 30, 2013 | -6.68% |
| Jun 30, 2013 | -13.60% |
| Mar 31, 2013 | -12.30% |
| Dec 31, 2012 | -8.20% |
| Sep 30, 2012 | -5.77% |
| Jun 30, 2012 | 4.74% |
| Mar 31, 2012 | 6.61% |
| Dec 31, 2011 | 5.60% |
| Sep 30, 2011 | 4.69% |
| Jun 30, 2011 | 4.45% |
| Mar 31, 2011 | 4.43% |
| Dec 31, 2009 | 1.87% |
| Sep 30, 2009 | 5.77% |